Biomea Fusion Analyst Ratings
EF Hutton Initiates Coverage On Biomea Fusion With Buy Rating, Announces Price Target of $128
Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $10
Scotiabank Maintains Biomea Fusion(BMEA.US) With Buy Rating, Raises Target Price to $41
A Quick Look at Today's Ratings for Biomea Fusion(BMEA.US), With a Forecast Between $10 to $60
Biomea Upgraded by Analysts After FDA Lifts Clinical Hold
Biomea Fusion Is Maintained at Equal-Weight by Barclays
Truist Securities Upgrades Biomea Fusion to Buy, Maintains Price Target to $54
A Quick Look at Today's Ratings for Biomea Fusion(BMEA.US), With a Forecast Between $9 to $60
Analysts Offer Insights on Healthcare Companies: Adverum Biotechnologies (ADVM), Biomea Fusion (BMEA) and Travere Therapeutics (TVTX)
Piper Sandler Remains a Buy on Biomea Fusion (BMEA)
Buy Rating Affirmed for Biomea Fusion With Promising BMF-219 Clinical and Regulatory Developments
Biomea Fusion Analyst Ratings
Rodman & Renshaw Upgrades Biomea Fusion to Buy, Announces $18 Price Target
Balanced Outlook With a Hold Rating for Biomea Fusion Amidst Upcoming Milestones and Clinical Developments
Truist Financial Maintains Biomea Fusion(BMEA.US) With Hold Rating
Truist Financial Issues a Hold Rating on Biomea Fusion (BMEA)
Biomea Fusion Analyst Ratings
Biomea Fusion Initiated at Overweight by Capital One
Capital One Initiates Coverage On Biomea Fusion With Overweight Rating, Announces Price Target of $25